Feiyiliu Mixture sensitizes EGFRDel19/T790M/C797S mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway

Feiyiliu Mixture sensitizes EGFRDel19/T790M/C797S mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway

Introduction: Osimertinib is a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, the emergence of acquired resistance due to the EGFR-Del19/T790M/C797S mutation limits the clinical...

Full description

Bibliographic Details
Main Authors: Jingjing Shi, Shaoyu Hao, Xiantao Liu, Yingying Li, Xin Zheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Pharmacology
Subjects:
Feiyiliu Mixture
osimertinib
acquired resistance
PRC1/Wnt/EGFR pathway
non-small cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1093017/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1093017/full

Similar Items